The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

GSK plc has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

The U.S. Food and Drug Administration has approved GSK plc (NYSE: GSK )’s asthma medication, Nucala, for expanded use in ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...